Is Lincoln Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers
- October 1, 2026
- Posted by: Neeraj Pandey
- Category: Market
Lincoln Pharmaceuticals CMP Rs 586 (01 Oct 2026). Market cap Rs 1,172 Cr. ROE 11.60%. P/E 12.15x versus Industry P/E 38.34x.
Quick Answer
Lincoln Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 11.60% return on equity and a P/E of 12.15x against an Industry P/E of 38.34x. Whether Lincoln Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Lincoln Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 586 as of 01 October 2026, within its 52-week range of Rs 440.00 to Rs 770.00. Lincoln Pharmaceuticals Ltd manufactures pharmaceutical formulations, with a significant export presence in emerging markets.
Lincoln Pharmaceuticals sits in the Healthcare sector, and its 11.60% ROE and 12.15x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Ltd manufactures pharmaceutical formulations, with a significant export presence in emerging markets. The stock is trading in the lower half of its 52-week range. At a market capitalisation of Rs 1,172 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Lincoln Pharmaceuticals the Best Stock in Its Sector?
Lincoln Pharmaceuticals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 11.60% ROE with a 12.15x P/E against the sector’s 38.34x Industry P/E. Lincoln Pharmaceuticals’ 12.15x P/E is far below the 38.34x Industry P/E despite an 11.60% ROE, making it look inexpensive relative to Kilitch Drugs India and other healthcare peers covered in this series.
| Metric | Lincoln Pharmaceuticals |
|---|---|
| CMP (NSE) | Rs 585.65 |
| 52-Week High / Low | Rs 770.00 / Rs 440.00 |
| Market Cap | Rs 1,172 Cr |
| P/E (TTM) vs Industry P/E | 12.15x vs 38.34x |
| P/B | 1.55 |
| ROE | 11.60% |
| EPS (TTM) | Rs 48.15 |
| Dividend Yield | 0.31% |
| Debt to Equity | 0.01 |
Compare Lincoln Pharmaceuticals Against Other Healthcare Sector Stocks
How Lincoln Pharmaceuticals Compares Against Its Healthcare Sector Peers
The table below sets Lincoln Pharmaceuticals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Lincoln Pharmaceuticals | 1,172 | 12.15 | 11.60% | 0.01 |
| Kilitch Drugs India | 771 | 26.41 | 10.79% | 0.32 |
| Jagsonpal Pharmaceuticals | 1,586 | 34.89 | 15.60% | 0.03 |
| Peer average (2 companies) | – | 30.65 | 13.20% | 0.17 |
Against this peer set, Lincoln Pharmaceuticals’s 11.60% ROE is below the 13.20% peer average, and its P/E of 12.15x runs below the peer average of 30.65x. Lincoln Pharmaceuticals’ 12.15x P/E is far below the 38.34x Industry P/E despite an 11.60% ROE, making it look inexpensive relative to Kilitch Drugs India and other healthcare peers covered in this series.
What Makes Lincoln Pharmaceuticals Worth Watching in Healthcare
- Well below Industry P/E: A 12.15x P/E against a 38.34x Industry P/E is a wide discount for a business with an 11.60% ROE.
- Near debt free: A debt to equity ratio of 0.01 gives Lincoln Pharmaceuticals significant balance sheet flexibility.
- Export-oriented formulations business: Manufacturing pharmaceutical formulations with a significant export presence to emerging markets gives Lincoln Pharmaceuticals a diversified customer base.
Lincoln Pharmaceuticals Valuation: Is It Justified?
Lincoln Pharmaceuticals’ 12.15x P/E is far below the 38.34x Industry P/E despite an 11.60% ROE, making it look inexpensive relative to Kilitch Drugs India and other healthcare peers covered in this series. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is LG Balakrishnan and Bros the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Lincoln Pharmaceuticals and other Healthcare sector stocks.
How to Track Lincoln Pharmaceuticals Before You Invest
Before deciding whether Lincoln Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Lincoln Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Lincoln Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 11.60% ROE and a P/E of 12.15x against a 38.34x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Lincoln Pharmaceuticals the best stock in its sector?
Ans. Lincoln Pharmaceuticals has a 11.60% ROE and trades at 12.15x P/E against a 38.34x Industry P/E, and compares below the peer average ROE of 13.20% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Lincoln Pharmaceuticals?
Ans. Lincoln Pharmaceuticals was trading at Rs 585.65 on the NSE as of 01 October 2026, within its 52-week range of Rs 440.00 to Rs 770.00.
What sector does Lincoln Pharmaceuticals belong to?
Ans. Lincoln Pharmaceuticals is classified under the Healthcare sector on Univest.
How does Lincoln Pharmaceuticals compare to its sector peers on P/E?
Ans. Lincoln Pharmaceuticals’s P/E of 12.15x is below the 30.65x average of the 2 named peers compared in this article.
What is Lincoln Pharmaceuticals’s return on equity?
Ans. Lincoln Pharmaceuticals reported a return on equity of 11.60%, which is below the 13.20% average of its named peers in this comparison.
Should I invest in Lincoln Pharmaceuticals based on its sector position?
Ans. Lincoln Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Lincoln Pharmaceuticals the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lincoln Pharmaceuticals has a 11.60% ROE and trades at 12.15x P/E against a 38.34x Industry P/E, and compares below the peer average ROE of 13.20% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Lincoln Pharmaceuticals?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lincoln Pharmaceuticals was trading at Rs 585.65 on the NSE as of 01 October 2026, within its 52-week range of Rs 440.00 to Rs 770.00.”}}, {“@type”: “Question”, “name”: “What sector does Lincoln Pharmaceuticals belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lincoln Pharmaceuticals is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Lincoln Pharmaceuticals compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lincoln Pharmaceuticals’s P/E of 12.15x is below the 30.65x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Lincoln Pharmaceuticals’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lincoln Pharmaceuticals reported a return on equity of 11.60%, which is below the 13.20% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Lincoln Pharmaceuticals based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lincoln Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}
